BioWorld Asia

March 22, 2006

MAb Causes Reactions In Phase I; Six In Hospital

The Medicines and Healthcare products Regulatory Agency (MHRA) in London is investigating the hospitalization of six men who took part in a Phase I trial of TGN1412, an immunomodulatory humanized agonistic anti-CD28 monoclonal antibody designed to treat chronic inflammatory conditions and leukemia. (BioWorld International) Read More

NicOx, Merck Sign Exclusive Antihypertensive Drug Deal

Fusion Molecule Boosts Plant Protein Production

EU Greets Landmark Decision In International Rules On GMOs

TeGenero Case May Prompt Tighter Clinical Trial Control

With More Data Pending, GW Mulls Sativex Filing

Santaris Bringing In EUR40M For Developing LNA Drugs

Biotech Boards Improve, But Executive Shortage Persists

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 3, 2026

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent

BioWorld Science

Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...